SEC Form 4 · accession 0001209191-18-004231
Foundation Medicine, Inc. · FMI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Ryan
Officer — Chief Financial Officer
Period of report
Jan 16, 2018
Accepted (ET)
Jan 18, 2018 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001488613
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 16, 2018 | S | 1,035 | $64.38 | D | 49,230 | D | |
| Common Stock | Jan 16, 2018 | M | 20,000 | $29.63 | A | 69,230 | D | |
| Common StockF1,F2 | Jan 16, 2018 | S | 20,000 | $64.38 | D | 49,230 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock (right to buy)F3 | $29.63 | Jan 16, 2018 | M | 20,000 | D | — | Feb 6, 2024 | Common Stock | 20,000 | 22,147 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2017.
- F2The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.65 to $68.65, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
- F3This option was granted on February 6, 2014 and vested in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018.